These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31893930)

  • 1. Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy.
    Spoladore R; Fragasso G; Pannone L; Slavich M; Margonato A
    Expert Opin Pharmacother; 2020 Feb; 21(2):233-242. PubMed ID: 31893930
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of peak provoked left ventricular outflow tract gradients on clinical outcomes in hypertrophic cardiomyopathy.
    Lu DY; Hailesealassie B; Ventoulis I; Liu H; Liang HY; Nowbar A; Pozios I; Canepa M; Cresswell K; Luo HC; Abraham MR; Abraham TP
    Int J Cardiol; 2017 Sep; 243():290-295. PubMed ID: 28747034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy.
    Maron BJ; Maron MS; Wigle ED; Braunwald E
    J Am Coll Cardiol; 2009 Jul; 54(3):191-200. PubMed ID: 19589431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.
    Sherrid MV; Arabadjian M
    Prog Cardiovasc Dis; 2012; 54(6):483-92. PubMed ID: 22687589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of present and future pharmaco-structural therapies for hypertrophic cardiomyopathy.
    Sawan MA; Prabakaran S; D'Souza M; Behbahani-Nejad O; Gold ME; Williams BR; Bilen O
    Clin Cardiol; 2024 Jan; 47(1):e24207. PubMed ID: 38269637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.
    Lu DY; Pozios I; Haileselassie B; Ventoulis I; Liu H; Sorensen LL; Canepa M; Phillip S; Abraham MR; Abraham TP
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical response to exercise in asymptomatic hypertrophic cardiomyopathy: a new description of outflow tract obstruction dynamics.
    Lafitte S; Reant P; Touche C; Pillois X; Dijos M; Arsac F; Peyrou J; Montaudon M; Ritter P; Roudaut R; Demaria A
    J Am Coll Cardiol; 2013 Aug; 62(9):842-50. PubMed ID: 23810875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hypertrophic cardiomyopathy.
    Enriquez AD; Goldman ME
    Ann Glob Health; 2014; 80(1):35-45. PubMed ID: 24751563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives.
    Ammirati E; Contri R; Coppini R; Cecchi F; Frigerio M; Olivotto I
    Eur J Heart Fail; 2016 Sep; 18(9):1106-18. PubMed ID: 27109894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy.
    Rosenzveig A; Garg N; Rao SJ; Kanwal AK; Kanwal A; Aronow WS; Martinez MW
    Expert Opin Pharmacother; 2023; 24(12):1349-1360. PubMed ID: 37272195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy.
    Fananapazir L; Epstein ND; Curiel RV; Panza JA; Tripodi D; McAreavey D
    Circulation; 1994 Dec; 90(6):2731-42. PubMed ID: 7994815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computed tomography imaging to quantify the area of the endocardial subvalvular apparatus in hypertrophic cardiomyopathy - Relationship to outflow tract obstruction and symptoms.
    Tajima M; Iguchi N; Utanohara Y; Hiroi Y; Mahara K; Niwa T; Takayama M; Sumiyoshi T; Tomoike H
    J Cardiovasc Comput Tomogr; 2016; 10(5):351-8. PubMed ID: 27498132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team.
    Pelliccia F; Alfieri O; Calabrò P; Cecchi F; Ferrazzi P; Gragnano F; Kaski JP; Limongelli G; Maron M; Rapezzi C; Seggewiss H; Yacoub MH; Olivotto I
    Int J Cardiol; 2020 Apr; 304():86-92. PubMed ID: 31983465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation between left ventricular outflow tract obstruction and left ventricular shape in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance imaging study.
    Martin R; Lairez O; Boudou N; Méjean S; Lhermusier T; Dumonteil N; Berry M; Cognet T; Massabuau P; Elbaz M; Rousseau H; Galinier M; Carrié D
    Arch Cardiovasc Dis; 2013; 106(8-9):440-7. PubMed ID: 23906680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertrophic cardiomyopathy: part 1 - introduction, pathology and pathophysiology.
    Varma PK; Neema PK
    Ann Card Anaesth; 2014; 17(2):118-24. PubMed ID: 24732610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy: JACC: Heart Failure State-of-the-Art Review.
    Ostrominski JW; Guo R; Elliott PM; Ho CY
    JACC Heart Fail; 2023 Jul; 11(7):735-748. PubMed ID: 37407153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy.
    Chase Cole J; Benvie SF; DeLosSantos M
    Clin Ther; 2024 Apr; 46(4):368-373. PubMed ID: 38508915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E/e' ratio and outcome prediction in hypertrophic cardiomyopathy: the influence of outflow tract obstruction.
    Lu DY; Haileselassie B; Ventoulis I; Liu HY; Liang HY; Pozios I; Canepa M; Phillip S; Abraham MR; Abraham T
    Eur Heart J Cardiovasc Imaging; 2018 Jan; 19(1):101-107. PubMed ID: 28977350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular outflow tract gradient is associated with reduced capillary density in hypertrophic cardiomyopathy irrespective of genotype.
    Güçlü A; Happé C; Eren S; Korkmaz IH; Niessen HW; Klein P; van Slegtenhorst M; Schinkel AF; Michels M; van Rossum AC; Germans T; van der Velden J
    Eur J Clin Invest; 2015 Dec; 45(12):1252-9. PubMed ID: 26444145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy.
    Maron MS; Olivotto I; Betocchi S; Casey SA; Lesser JR; Losi MA; Cecchi F; Maron BJ
    N Engl J Med; 2003 Jan; 348(4):295-303. PubMed ID: 12540642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.